Indianapolis, IN15 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Indianapolis, IN

Find 15 actively recruiting myalgic encephalomyelitis clinical trials in Indianapolis, IN. Connect with local research sites and explore new treatment options.

15
Active Trials
11
Sponsors
2,919
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Indianapolis

RecruitingIndianapolis, INNCT07044336

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or p...

700 participants
AstraZeneca
View Study Details
RecruitingIndianapolis, INNCT01760005

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by ...

490 participants
Washington University School of Medicine
View Study Details
RecruitingIndianapolis, INNCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing...

360 participants
National Institute on Drug Abuse (NIDA)
View Study Details
RecruitingIndianapolis, INNCT05552157

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 wil...

280 participants
Washington University School of Medicine
View Study Details
RecruitingIndianapolis, INNCT06647498

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individu...

280 participants
Washington University School of Medicine
View Study Details
RecruitingIndianapolis, INNCT05797831

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The ...

268 participants
Kartos Therapeutics, Inc.
View Study Details
RecruitingIndianapolis, INNCT05462106

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with...

140 participants
AC Immune SA
View Study Details
RecruitingIndianapolis, INNCT06049680

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipi...

100 participants
Fresenius Kabi
View Study Details
RecruitingIndianapolis, INNCT05035030

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic...

70 participants
Albireo, an Ipsen Company
View Study Details
RecruitingIndianapolis, INNCT06384573

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to...

65 participants
Washington University School of Medicine
View Study Details
RecruitingIndianapolis, INNCT05154487

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by e...

51 participants
GOG Foundation
View Study Details
RecruitingIndianapolis, INNCT07096843

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN...

45 participants
Climb Bio, Inc.
View Study Details
RecruitingIndianapolis, INNCT05521438

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle...

30 participants
Quoin Pharmaceuticals
View Study Details
RecruitingIndianapolis, INNCT05789056

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome...

20 participants
Quoin Pharmaceuticals
View Study Details
RecruitingIndianapolis, INNCT03266640

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovi...

20 participants
New York Medical College
View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Indianapolis

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 15 myalgic encephalomyelitis clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 2,919 participants. Research is being sponsored by AstraZeneca, Washington University School of Medicine, National Institute on Drug Abuse (NIDA) and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Indianapolis — FAQ

Are there myalgic encephalomyelitis clinical trials in Indianapolis?

Yes, there are 15 myalgic encephalomyelitis clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Indianapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.

Are clinical trials in Indianapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 15 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated March 2, 2026 from ClinicalTrials.gov